262
Views
0
CrossRef citations to date
0
Altmetric
Anemia and Hematologic Disorders

Hemoglobin level and erythropoietin response in hemodialysis patients: what can we pay attention to?

, , &
Article: 2353338 | Received 22 Apr 2024, Accepted 03 May 2024, Published online: 13 May 2024

References

  • Cui L, Zhang L, Li J, et al. Correlation between ultrafiltration rate and hemoglobin level and erythropoietin response in hemodialysis patients. Ren Fail. 2024;46(1):2296609. doi:10.1080/0886022X.2023.2296609.
  • Zhan Y, Chen R, Zheng W, et al. Association between serum magnesium and anemia: China health and nutrition survey. Biol Trace Elem Res. 2014;159(1-3):39–45. doi:10.1007/s12011-014-9967-x.
  • Biyik Z, Yavuz YC, Altintepe L. Association between serum magnesium and anemia in patients with chronic kidney disease. Int Urol Nephrol. 2020;52(10):1935–1941. doi:10.1007/s11255-020-02525-8.
  • Yu L, Song J, Lu X, et al. Association between serum magnesium and erythropoietin responsiveness in hemodialysis patients: a cross-sectional study. Kidney Blood Press Res. 2019;44(3):354–361. doi:10.1159/000500921.
  • Pethő ÁG, Tapolyai M, Browne M, et al. Hypomagnesemia as a risk factor and accelerator for vascular aging in diabetes mellitus and chronic kidney disease. Metabolites. 2023;13(2):306. doi:10.3390/metabo13020306.
  • Ingrasciotta Y, Lacava V, Marcianò I, et al. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study. BMC Nephrol. 2019;20(1):359. doi:10.1186/s12882-019-1554-0.
  • Sakaguchi Y, Hamano T, Wada A, et al. Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis. J Am Soc Nephrol. 2019;30(6):1037–1048. doi:10.1681/ASN.2018101007.
  • Weir MR. Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents. Am J Nephrol. 2021;52(6):450–466. doi:10.1159/000516901.
  • National Clinical Research Centre for Kidney Disease. Summary of Chinese guidelines for the diagnosis and treatment of chronic kidney disease mineral and bone abnormalities. J Nephrol Dialy Transplant. 2019;28(1):52–57.